Deferring systemic therapy may improve survival outcomes in carefully selected patients with metastatic renal cell carcinoma, new data suggest.
Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results